Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new drug combo push CML into deep remission?

NCT ID NCT03906292

NEW Ongoing Disease control Sponsor: University of Jena Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This phase 2 trial is testing whether adding the experimental drug asciminib to standard treatments (imatinib, nilotinib, or dasatinib) can achieve deeper molecular responses in adults newly diagnosed with chronic-phase chronic myeloid leukemia (CML). Participants receive one of several combination regimens or asciminib alone, and the study measures how well the leukemia is suppressed at a molecular level. The goal is to see if these combinations can improve treatment outcomes and quality of life for people with this blood cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
asciminib combined with imatinib, nilotinib, or dasatinib
What this could lead to
If successful, this could lead to more effective first-line treatment options for chronic myeloid leukemia, potentially achieving deeper remission and better long-term outcomes.
What could go wrong
This is a phase 2 trial, so results are preliminary. The combinations may not improve response rates over standard therapy, and there are risks of side effects from the drugs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA

Contacts and locations

Locations

  • Brüderkrankenhaus St. Josef Paderborn

    Paderborn, 33098, Germany

  • Charite Universitätsmeditin Berlin, Campus Virchow Klinikum

    Berlin, 13353, Germany

  • GOKOS GmbH

    Dresden, 01307, Germany

  • Gemeinschaftspraxis Dres. Müller/ Kröning/ Jentsch-Ullrich/ Tietze/ Krogel

    Magdeburg, 39104, Germany

  • Klinikum Bremen Mitte

    Bremen, 28177, Germany

  • Klinikum Chemnitz gGmbH

    Chemnitz, 09113, Germany

  • Klinikum rechts der Isar

    München, 81675, Germany

  • Krankenhaus Barmherzige Brüder Regensburg

    Regensburg, 93049, Germany

  • Universitätsklinikum Aachen Medizinische Klinik IV

    Aachen, 52074, Germany

  • Universitätsklinikum Bonn

    Bonn, 53105, Germany

  • Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden

    Dresden, 01307, Germany

  • Universitätsklinikum Erlangen

    Erlangen, 91054, Germany

  • Universitätsklinikum Essen

    Essen, 45122, Germany

  • Universitätsklinikum Frankfurt

    Frankfurt, 60590, Germany

  • Universitätsklinikum Freiburg

    Freiburg im Breisgau, 79106, Germany

  • Universitätsklinikum Gießen und Marburg

    Marburg, 35043, Germany

  • Universitätsklinikum Jena

    Jena, 07747, Germany

  • Universitätsklinikum Leipzig

    Leipzig, 04103, Germany

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

  • Universitätsmedizin Mannheim

    Mannheim, 68169, Germany

  • Universitätsmedizin der Johannes- Gutenberg Universität Mainz

    Mainz, 55131, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.